BOT
Botanix Pharmaceuticals Ltd
$0.0080
▼ -11.11%
Market cap
$22M
Turnover
$378,582
Last price
$0.0080
Day change
-11.11%
Announcements
6
Range, past year
Open 0.130 · Low 0.008 · Now 0.008 · High 0.475
Open BOT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
BOT momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
34/100
Wyckoff phase
Downtrend37d
Trend stage
Neutral
1 Day
-11.1%
1 Week
-20.0%
1 Month
-38.5%
1 Year
-93.8%
RSI
34
Avg daily range
20.4%
Botanix Pharmaceuticals Ltd scores 34 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Downtrend, where it has been for 37 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.94 — highly linear uptrend
Points to watch
- 60d drawdown -61.9%
- High volatility (ATR 20.4%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsBOT announcements
Recent price-sensitive releases.
- 2026-10-27 Botanix Quarterly Activities Report and Appendix 4C Q1 FY27 Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-08-26 Appendix 4E & Annual Report for the Year Ended 30 June 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-27 Botanix Quarterly Activities Report and Appendix 4C Q4 FY26 Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-13 Notice of Allowance for US patent on Sofdra drug substance
- 2026-07-07 Intention to Grant a European patent on Sofdra applicator
- 2026-04-29 Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
More Health Care stocks
Most traded in the same sector.